Linker Information
General Information of This Linker
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
CN117337196A Compound91 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ -20% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ -5% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 2% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 5% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 10% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 10% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 18% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 25% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 42% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 50% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 55% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 70% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||